Prestige Consumer Healthcare Inc. delivered another year of consistent sales and earnings per share growth, with record fourth quarter sales performance driven by International business strength, growth in various categories and brands in North America, and success in eCommerce.
Record reported revenues in Q4 fiscal 2025 of $296.5 million, a 7.0% increase from the prior year.
Organic revenue grew 7.9% in Q4, reflecting broad-based growth across North America and International business segments.
Diluted EPS for Q4 fiscal 2025 was $1.00, compared to $0.98 in the prior year comparable period.
Non-GAAP adjusted diluted EPS for Q4 fiscal 2025 was $1.32, up from $1.02 in the prior year comparable period.
For fiscal 2026, Prestige Consumer Healthcare Inc. anticipates achieving organic revenue growth of approximately 1% to 2% and diluted EPS of $4.70 to $4.82, equating to mid-to high-single digit earnings growth.
Visualization of income flow from segment revenue to net income